Company profile
Anixa Biosciences, Inc.
NASDAQ: ANIX · Healthcare · Biotechnology
#1003 of 1,422 Healthcare companies by revenue41st-percentile growth
EA Score
52DFH 43DQ 73GM 37SS 58
v0.1 · 65/100 weight · provisional
↑ listing tenure, Altman-Z · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$10.9M
Employees
4
as of 2026-08-18
Market cap
$116.0M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$210.0k$210.0k2024
Net income-$10.9M-$10.9M2025
Operating income-$11.7M-$11.7M2025
Total assets$16.1M$16.1M2025
Liabilities$2.1M$2.1M2025
Equity$15.2M$15.2M2025
Revenue trend
FY2015 – FY2024 · USD
FY15
FY17
FY17
FY18
FY20
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2019
By product
Patent Licensing100%
By geography
Not disclosed.
The read
What is Anixa Biosciences, Inc.’s revenue?
Anixa Biosciences, Inc. booked $210.0k in FY2024 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -5203.3% net margin.
Peers · Healthcare
Family Office of America Inc.37DHAVN Life Sciences Inc.——Brain Scientific Inc.——GlucoTrack, Inc.28DSharps Technology, Inc.33DLixte Biotechnology Holdings, Inc.40DNeighbors
Santa Clara →Key facts
CEOAmit Kumar
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Jose, CA
ExchangeNASDAQ: ANIX
Employees4
IPO date1983-10-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.